Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Open-label Safety and Immunogenicity Study of GARDASIL 9 in 9- to 26-Year-Old Females and Males in Vietnam
2017-001205-33Phase 3
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN) and 7 more, sponsored by Merck & Co. Primary endpoint: Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)cervical intraepithelial neoplasia (CIN)Vulval carcinomavulvar intraepithelial neoplasia (VIN)
Beyond the preview
Go deeper on 2017-001205-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001205-33.